Navigation Links
Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
Date:7/25/2011

PRINCETON, N.J. , July 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2011.

Financial ResultsRevenues were $0.2 million during the quarter ended June 30, 2011 compared to $0.2 million for the quarter ended June 30, 2010 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended June 30, 2011 was $22.3 million. Pharmasset held $188.2 million in cash and cash equivalents as of June 30, 2011.

Total operating expenses for the quarter ended June 30, 2011 were $22.6 million as compared to $15.7 million for the same period in 2010.

Pharmasset reported a net loss of $22.6 million, or $0.60 per share, for the quarter ended June 30, 2011, as compared to a net loss of $16.0 million, or $0.50 per share, for the quarter ended June 30, 2010.

Recent Operational Highlights:-- Bristol-Myers Squibb initiated a combination trial with BMS-790052 and PSI-7977

-- Completed enrollment of ELECTRON's original four arms with PSI-7977

-- Expanded the ELECTRON trial with the addition of three new treatment arms

-- We were granted a US patent (US patent 7,964,580) titled 'Nucleoside Phosphoramidate Prodrugs' covering PSI-7977

-- Pharmasset and Tibotec announced a clinical collaboration to combine PSI-7977 and Tibotec's TMC435, a protease inhibitor

-- Reported SVR24 data from PROTON trial with PSI-7977 in genotype 2 or 3 patients

-- Roche disclosed that it expects to file, in 2014, an application for marketing approval of mericitabine

"Pharmasset had a very successful f
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
2. Pharmasset to Present at Two Upcoming Investor Conferences
3. Pharmasset Reports Fiscal Second Quarter 2011 Financial Results
4. Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes
5. Pharmasset to Webcast an Investor Event From the EASL Meeting
6. Pharmasset to Present at Three Upcoming Investor Conferences
7. Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
8. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
9. Pharmasset Announces Exercise of Underwriters Overallotment Option
10. Pharmasset Prices Public Offering of Common Stock
11. Pharmasset Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ) ... ended June 28, 2014. Third Quarter Financial ... to $632.6 million, reflecting operational growth of 0.5% and ... same period in the prior year. , Revenues ... Breast Health revenues grew 3.5%. , GYN Surgical ...
(Date:7/30/2014)... CUPERTINO, Calif. , July 30, 2014 ... ) second quarter 2014 financial results press release, you ... will be broadcast live over the internet on Thursday, ... pm Pacific Time). A live audio webcast ... homepage at http://www.durect.com and clicking "Investor Relations."  ...
(Date:7/30/2014)... PuraMed BioScience ® , Inc., (OTCPink:PMBS), ... medicinal and healthcare products, announced today that the ... with the name,s red and yellow logo. The ... MigraPure ®  going forward. The new name, ... migraine pain reliever will be reintroduced into selected ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3
... Jan. 11, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ... the Company to address the dual epidemics of diabetes and ... the year and place the Company on the path to ... presented by Daniel M. Bradbury, president and chief executive officer, ...
... 11 Spherix Inc. (Nasdaq: SPEX ), an innovator ... and regulatory consulting services to food, supplement, biotechnology and pharmaceutical ... be presenting at the Annual OneMedPlace Finance Forum, which is ... Francisco, CA. Dr. Lodder will deliver the Company,s corporate ...
Cached Medicine Technology:Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 2Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference 3Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 2Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco 3
(Date:7/30/2014)... Steven Reinberg HealthDay ... Each year in the United States, at least 2,000 Americans ... officials said Wednesday. Heat waves, heat stroke or sun ... reported between 2006 and 2010, according to the U.S. Centers ... -- a severe loss of body heat -- accounted for ...
(Date:7/30/2014)... 2014 Volunteers from the Church of ... abuse this summer with massive distribution of Truth ... find these volunteers on Strøget, the famous Copenhagen walking ... its shopping and its ambiance, some quarter of a ... summer day. , These activities are part of ...
(Date:7/30/2014)... The family of a Vermont man ... Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ) alleging his death ... reports. According to the complaint, which was filed in ... July 25th, the decedent had been taking Xarelto for ... bleed that ultimately led to his death on August ...
(Date:7/30/2014)... Hamilton Facial Plastic Surgery ... Carmel office on July 30th. After months of planning, ... to the state-of-the-art suite, located only steps away from ... allow for one-on-one patient comfort, shorter wait times, and ... Dr. Hamilton’s new office-suite will continue to provide the ...
(Date:7/30/2014)... DRE Medical — a leading medical ... of its Medical Trade Shows & Conventions Calendar ... and equipment vendors. , The calendar is a continually-updating ... United States and around the world. Hundreds of entries ... is always growing. , Information listed on each trade ...
Breaking Medicine News(10 mins):Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:DRE Launches Online Interactive Medical Trade Show Calendar 2
... safe and may produce beneficial changes in the brains ... to an article posted online today that will appear ... Neurology, one of the JAMA/Archives journals. , In patients ... myelin sheaths that protect nerve cells in the brain ...
... pressure may be associated with a decreasing peripheral field ... eye pressure remains low overall, according to a report ... of the JAMA/Archives journals. , Prevention of further visual ... authors write as background information in the article. Previous ...
... 13, 2007, Paying out certain types of government aid in ... harmful and often fatal drug binges, according to a new ... Economics that links the monthly arrival of disability checks with ... findings by researchers at the University of California, Santa Cruz ...
... disaster strikes, causing structural damage to DNA, players in ... contain the wreckage, scientists at The University of Texas ... edition of Cell. , This connection between a signaling ... known as chromatin remodeling "opens an entirely new category ...
... New research from scientists at UT Southwestern Medical ... the importance of preventing recurring acid reflux while also ... turn potentially cancerous. , In research published in July ... disease, particularly those with a complication of acid reflux ...
... 2007) Surgeons may have a new patient ... some of the concerns associated with the current ... August issue of the Journal of the American ... (rhThrombin) reduces the risk of surgical complications associated ...
Cached Medicine News:Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2Health News:Fluctuating eye pressure associated with visual field deterioration in glaucoma patients 2Health News:Disability payments may spur drug abuse 2Health News:Chromatin remodeling complex connected to DNA damage control 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 2Health News:Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer 3Health News:New study shows promise in reducing surgical risks associated with surgical bleeding 2
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: